Case 1:16—cv—0OO64—SLR Document 4 Filed 02/04/16 Page 1 of 1 Page|D #: 234
`
`
`
`AO120(Re\/.0‘ ' ‘
`
`T0:
`
`Mag} smp 3
`Director“ of the US. Patent and Trademark Gffice
`R0. Box 145%}
`Alexzaxndria, VA, 22313-1450
`
`REP(}R’I" ON THE;
`FILING OR IEETERNEENATIGN GE" AN
`ACTHEN REGARBENG A PATENT (ER
`TRAE}}j‘MAR}{
`
`in Compliance wifln 35 U.S.C.
`
`290 and/er 15 U.S.C. § 1116 yeu are hereby advised that a (:()u1‘1: action has
`
`files} in the
`
`Di,stri,(:t Court
`
`TO? the D§S’[!”iC’[ Of Deiaware
`
`on the following
`
`Trademarks or
`
`BHI’a31.et1is.
`
`(
`
`the patent aciimx im/elves 35 U .S.C. § 292.):
`
`DOCKET NO.
`
`DATE FELED
`
`Us. DESTRHCT COURT
`
`PLALWEFF
`BAYER ENTELLECTLJAL PFEQPERTY GMBH, et ai.
`
`ENVAGEN PHARMACELJTTCALS, iNC.
`
`2/4/2016
`
`.
`
`for the District of Delaware
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADE]‘vEAR}<
`
`V
`4 T‘
`HOLDER OF PAAENT OR TRADEMARK
`
`1 7,157,456 82
`
`7,585,860 82
`
`1/2/2007
`
`9/8/2009
`
`Bayer inteilectuai Property Gmbi--i
`
`Bayer inteiieetuai Property GmbH
`
`DATE INCLUDED
`
`PATENT‘ OR
`TRADEMARK NO.
`
`DATE OF FATE NT
`QR TRADEMARK
`
`in the ab-;)Ve—————e11ii,t1ed case. the fellewing deei,si,en has been reheiereei er judgement issued:
`DECKS ION/JUDG EM ENT
`
`(BY) DEPUTY CLERK
`
`Copy 1-----Uper: initisaiitm of aeiiert, msaifl this eepy ts) E)irecta)r Copy 3------Upon terrnirtsztixm 05’ aeiien, msaifi this copy ts; Dires:ter
`Cepy 2-----Upon filing decuaneazt sadding psateams), msaifl this cepy ta) Birecteyr Cepy 4------Case fiie (zippy
`
`MYLAN - EXHIBIT 1006 - 1O30a(TJ[ 1 of 9
`
`0001
`
`MYLAN - EXHIBIT 1006 - Part 1 of 9
`
`

`
`Case 1:16—cv—00242—UNA Document 4 Filed 04/08/16 Page 1 of 1 Page|D #: 159
`
`
`
`AO120(Re\/.0‘ ' ‘
`
`T0:
`
`Mag} smp 3
`Director“ of the US. Patent and Trademark Gffice
`R0. Box 145%}
`Alexzaxndria, VA, 22313-1450
`
`REP(}R’I" ON THE;
`FILING OR IEETERNEENATIGN GE" AN
`ACTHEN REGARBENG A PATENT (ER
`TRAE}}j‘MAR}{
`
`in Compliance wifln 35 U.S.C.
`
`290 and/er 15 U.S.C. § 1116 yeu are hereby advised that a (:()u1‘1: action has
`
`files} in the
`
`Di,stri,(:t Court
`
`f0? the D§S’[!”iC’[ Of Deiaware
`
`on the following
`
`Trademarks or
`
`BHI’a31.et1is.
`
`(
`
`the patent aciimx im/elves 35 U .S.C. § 292.):
`
`DOCKET NO.
`
`DATE FELED
`
`Us. DESTRHCT COURT
`
`PLALWEFF
`BAYER ENTELLECTLJAL PFEQPERTY GMBH, et ai.
`
`MEG-RC) LABS LTD., MECP;O LABS USA ENC.
`
`4/8/20?6
`
`.
`
`for the District of Delaware
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF PATENT
`OR TRADE]‘vEAR}<
`
`V
`$ T‘
`HOLDER OF PAAENT OR TRADEMARK
`
`1 7,585,850 32
`
`9/8/2009
`
`Bayer inteilectuai Property Gmbi--i
`
`7,592,339 82
`
`9/22/2009
`
`Bayer inteiiectuai Property GmbH
`
`'47
`
`-—
`_—
`
`DATE INCLUDED
`
`PATENT OR
`TRADEMARK NO.
`
`DATE OF FATE NT
`QR TRADEMARK
`
`in the ab-;)Ve—————e11ii,t1ed case. the fellewing deei,si,en has been reheiereei er judgement issued:
`DECKS ION/JUDG EM ENT
`
`(BY) DEPUTY CLERK
`
`Copy 1-----Uper: initisaiitm of aeiiert, msaifl this eepy ts) E)irecta)r Copy 3------Upon terrnirtsztixm 05’ aeiien, msaifi this copy ts; Dires:ter
`Cepy 2-----Upon filing decuaneazt sadding psateams), msaifl this cepy ta) Birecteyr Cepy 4------Case fiie (zippy
`
`0002
`
`0002
`
`

`
`
`
`LII’
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMEVT OF COMMERCE
`United States Patent and Trademark Office
`Address. COMMISSIONER FOR PATENTS
`,. B0x1450
`exaJrdI‘ia,Vi.1g1.11ia 22313-1450
`WWVl.'.HSpt0.goV
`
`APPLICATION \1 UMBER
`
`F ING OR 371 (C) DATE
`
`FIRST NAMED APPLICANT
`
`ATTY. DOCKET NO./TITLE
`
`12/027,553
`
`02/07/2008
`
`Alexander Straub
`
`11987-00030-US
`CONFIRMATION NO. 5078
`
`21839
`
`BUCHANAN, INGERSOLL & ROONEY PC
`POST orrnce BOX 1404
`ALEXANDRIA, VA 22313-1404
`
`POA ACCEPTANCE LETTER
`
`H||\I\I\IIHN||I\\I|fllflI|I\\\I|\\\|II\|I\|l|H\HII|\IN\|IlI\III|H\||H|\IHHII
`000000057879665
`
`Date Mailed: 12/05/2012
`
`NOTICE OF ACCEPTANCE OF POWER OF ATTORNEY
`
`This is in response to the Power of Attorney filed 11/21/2012.
`
`The Power of Attorney in this application is accepted. Correspondence in this application will be mailed to the
`above address as provided by 37 CFR 1.33.
`
`latesfail
`
`Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101
`
`page 1 of 1
`
`0003
`
`0003
`
`

`
`
`
`‘LII’
`
`»
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMEVT OF COMMERCE
`United States Patent and Trademark Office
`Address. COMMISSIONER FOR PATENTS
`,. Box 1450
`exandria, Vi.1gLnia 22313-1450
`WWVl.'.HSpt0.goV
`
`APPLICATION \1 UMBER
`
`F ING OR 371 (C) DATE
`
`FIRST NAMED APPLICANT
`
`ATTY. DOCKET NO./TITLE
`
`12/027,553
`
`02/07/2008
`
`Alexander Straub
`
`11987-00030-US
`CONFIRMATION NO. 5078
`
`23416
`
`CONNOLLY BOVE LODGE & HUTZ, LLP
`P o BOX 2207
`WILMINGTON, DE 19899
`
`POWER OF ATTORNEY NOTICE
`
`lllllllllllllllllIllllllllfllllllllllllIlllllllllIllllllllllllllllllllllllllllllllllllllllll
`000000057879648
`
`Date Mailed: 12/05/2012
`
`NOTICE REGARDING CHANGE OF POWER OF ATTORNEY
`
`This is in response to the Power of Attorney filed 11/21/2012.
`
`- The Power of Attorney to you in this application has been revoked by the assignee who has intervened as
`provided by 37 CFR 3.71. Future correspondence will be mailed to the new address of record(37 CFR 1.33).
`
`latesfail
`
`Office of Data Management, Application Assistance Unit (571) 272-4000, or (571) 272-4200, or 1-888-786-0101
`
`page 1 of 1
`
`0004
`
`0004
`
`

`
`P?O.'SBl8t) {1 1 -(38)
`Approved for use through 1113012021. OMB (1651-0035
`U.S. Patent and Trademark Office; LJ.S. QEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act 051995, no persons are required to respond to a collection of information unless it dispiays a vaiid OMB controi number.
`POWER OF ATTORNEY T0 PROSEC-UTE APPLICATIONS BEFORE THE USPTO
`
`I
`
`Z
`
`I hereby revoke all previous powers of attorne ven h lication identified in the attached statement under
`37 CFR 3.73 b .
`i hereby appoint:
`
`
`
`
`Practitioners associated with the Customer Number:
`OR
`
`21839
`
`[:1 Practitioner{s} named below (if more than ten patent practitioners are to be named, then a customer number must be used):
`Name
`Registration
`5 ‘
`Number
`-.
`
`as artorrzey(s) or agent{s) to represent the undersigned before the United States Patent and Trademark Office (USPTO} in connection with
`
`any and alt patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents
`attached to this form in accordance with 37 CFR 3.'r'3(b).
`
`
`
`
`
`Please change the correspondence address for the appficalion identified in the attached statement under 37 CFR 3.'I’3(b) to:
`
`
`
`
`
`The address associated with Customer Number:
`
`21839
`
`OR
`
`Firm or
`
`Individual Name
`
`Assignee Name and Address:
`
`BAYER ENTELLECTUAL PROPERTY GMBH
`/-\lfred—Nobe|—Strasse 10
`40789 Evlonheim Gerrnany
`
`
`
`
`
`A copy of this form, together with a statement under 3? CFR 3.73(b) (Form P"%'Oi'SBI96 or equivalent) is required to be
`fited in each appiication in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of
`the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee,
`
`
`and must identit the a o iication in which this Power of Attorne is to be filed.
`SEGNATURE of Assignee of Rcord
`. ._sc signature and title is supplied bcichorizcd to act on behalf of thc assigncc
`i 444...
`9<>«<2-»u—c>e
`er. i~\\e>©Ur\clie.t' cw.
`t’:;':.~tant(bum
`This collection of information is required by 3? 9' R 1.31. ‘$.32, and 1.33. "fhe information is required to obtain or retain a benefit by the public which is to file (and
`by the USPTO to process) an application. Co fideetialityés governed by 35 U.$,C. 122 and 3? CFR 1.13 and 1.14. This coiiection is estimated to take 3 minutes
`to complete, inciuding gathering. preparing, and submitting the compieted application form to the USPTO. Time will vary depending upon the indlvldtzal case. Any
`comments on the amount of time you require to corrspfiete this form andfor suggestions for reducing this burden. should be sent to the Chief information Officer,
`US. ‘S-’atent and Trademark Office, iJ.S. Department of Commerce. PO‘ Box 1450. Aiexandria. VA 22313-1450. DO NO’? SEND FEES OR COMPLETED
`FORMS TO THIS ADDRESS. SEND TO: Commissioner for ?atents, PO. Box 1450, Alexandria, VA 22313-1450.
`
`
`
`
`
`
`
`/ '
`
`Jfyou need assistance In compfeting the form, cal! 1-800~PTO-9199 and select option 2.
`
`0005
`
`0005
`
`

`
`Privacy Act Statement
`
`The Privacy Act of 1974 (P.i... 93-579) requires that you be given certain information in connection
`with your submission of the attached form reiated to a patent appiication or patent. Accordingiy,
`pursuant to the requirements of the Act, please be advised that: (1) the general authority for the
`collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary;
`and (3) the principal purpose for which the information is used by the US. Patent and Trademark
`Office is to process and/or examine your submission related to a patent application or patent. If you do
`not furnish the requested information, the U5. Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or
`abandonment of the application or expiration of the patent.
`
`The information provided by you in this form will be subject to the foilowing routine uses:
`
`1. The information on this form wiii he treated confidentially to the extent ailowed under the
`Freedom of information Act (5 U.S.C. 552) and the Privacy Act {5 U.S.C 552a). Records from
`this system of records may be disciosed to the Department of Justice to determine whether
`disclosure of these records is required by the Freedom of information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of
`presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to
`opposing counsel in the course of settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of
`Congress submitting a request invoiving an individual, to whom the record pertains, when the
`individuai has requested assistance from the Member with respect to the subject matter of the
`record.
`
`A record in this system of records may be disclosed, as a routine use, to a contractor of the
`Agency having need for the information in order to perform a contract. Recipients of
`information shail be required to comply with the requirements of the Privacy Act of 1974, as
`amended, pursuant to 5 U.S.C. 552a(rn).
`A record reiated to an international Appiication filed under the Patent Cooperation Treaty in
`this system of records may be disclosed, as a routine use, to the international Bureau of the
`World lrilellectua! Property Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disciosed, as a routine use, to another federal
`agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to
`the Atomic Energy Act (42 U.S.C. 2’i8(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator,
`General Services, or his/her designee, during an inspection of records conducted by GSA as
`part of that agency’s responsibility to recommend improvements in records management
`practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall
`be made in accordance with the GSA regulations governing inspection of records for this
`purpose, and any other relevant (r'.e., GSA or Commerce) directive. Such disclosure shalt not
`be used to make determinations about individuais.
`A record from this system of records may be disclosed, as a routine use, to the pubiic after
`either publication of the appiication pursuant to 35 U.S.C. ‘i22(io) or issuance of a patent
`pursuant to 35 U.S.C. 151. Further, a record may be disciosed, subject to the iimitations of 37
`CFR 1.14, as a routine use, to the puhtic if the record was filed in an application which
`became abandoned or in which the proceedings were terminated and which apptication is
`referenced by either a published application, an apptication open to public inspection or an
`issued patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State,
`or local law enforcement agency, if the USP“i"0 becomes aware of a vioiation or potential
`vioiation of law or reguiation.
`
`0006
`
`0006
`
`

`
`PTO/SB/96 (07-09)
`Approved for use through 07/31/2012. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.
`
`STATEMENT UNDER 37 CFR 3.73(b[
`
`Applicant/patent Owner: BAYER INTELLECTUAL PROPERTY GMBH
`
`Application No./Patent No.: 7.585.850
`Titled:
`
`Filed/Issue Date: September 3. 2009
`
`SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION
`
`BAYER INTELLECTUAL PROPERTY GMBH
`(Name of Assignee)
`
`I a
`
`Corporation
`(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.
`
`states that it is:
`
`the assignee of the entire right, title, and interest in;
`
`an assignee of less than the entire right, title, and interest in
`(The extent (by percentage) of its ownership interest is
`
`%); or
`
`the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
`
`the patent application/patent identified above, by virtue of either:
`
`A. I:
`
`OR
`
`B.
`
`An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in
`the United States Patent and Trademark Office at Reel
`, Frame
`, or for which a
`copy therefore is attached.
`
`A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
`1_ From;
`INVENTORS
`To; BAYER AKTIENGESELLSCHAFT
`
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel 020729
`
`,
`
`Framem 04
`
`,
`
`or for which a copy thereof is attached.
`
`2. From: BAYER AKTIENGESELLSCHAFT
`
`To: BAYER HEALTHCARE AG
`
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel 020729
`
`,
`
`Framem 25
`
`,
`
`or for which a copy thereof is attached.
`
`3, From; BAYER HEALTHCARE AG
`
`To; BAYER SCHERING PHARMA AG
`
`The document was recorded in the United States Patent and Trademark Office at
`
`Ree, 022575
`
`Frame 0337
`
`,
`
`or for which a copy thereof is attached.
`
`Additional documents in the chain of title are listed on a supplemental sheet( ).
`
`As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was,
`or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
`
`{NOTE: A separate copy (ie., a true copy of the original assignment document(s)) must be submitted to Assignment Division in
`accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. Si MPEP 302.08]
`
`The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
`
`/Christine M Hansen/
`Signature
`
`Christine M. Hansen
`
`November 21, 2012
`Date
`
`Attorney
`
`Title
`Printed or Typed Name
`This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to
`process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including
`gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time
`you require to complete this form andlor suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S.
`Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner
`for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`If you need assistance in completing the fomi, call 1-800—PTO-9199 and select option 2.
`
`0007
`
`0007
`
`

`
`From: BAYER SCHERING PHARMA AG
`
`To: BAYER PHARMA AKTIENGESELLSCHAFT
`
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel 026661,
`
`Frame 0406, or for which a copy of thereof is attached.
`
`From: BAYER PHARMA AKTIENGESELLSCHAFT To: BAYER INTELLECTUAL PROPERTY GMBHV
`
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel 029277,
`
`Frame 0713, or for which a copy of thereof is attached.
`
`0008
`
`0008
`
`

`
`Electronic Acknowledgement Receipt
`
`International Application Number:
`
`Title of Invention:
`
`SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD
`COAGULAHON
`
`First Named Inventor/Applicant Name:
`
`Application Type:
`
`Utility under 35 USC111(a)
`
`Payment information:
`
`Document Description
`
`File Size(Bytes)/
`Message Digest
`
`Pages
`Multi
`Part /.zip (if appl.)
`
`File Listing:
`
`Document
`Number
`
`Information:
`
`0009
`
`Power of Attorney
`
`PowerOfAttorney.pdf
`
`173991
`
`07b7b6bfc4d4e75580e504I bI 6ad3d0859 '
`(e705
`
`0009
`
`

`
`Assignee showing of ownership per 37
`CFR 373.
`
`O08i565000021.pdf
`
`5812ef6a8b9fcd729c52772ec2751580ib45
`220e
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`lfa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and ofthe International Filing Date (Form PCT/R0/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0010
`
`0010
`
`

`
`FTOISBIBM (124.18)
`Appnoved for use through 11/30/2011. OMB 0551-0035
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Undertha Pa - rwork Reduction Act M1995. no - mans am - uirad to res nd to a collection ofinfozmatlon un less it disla s a valid OMB control number:
`
`
`
`
`PATENT — POWER OF ATTORNEY
`Patent Number
`7.585.350
`OR
`issue Date
`September 8, 2009
`REVOCATION OF POWER OF ATTORNEY
`Hrst Named inventor
`Alexander Stra ttb
`WITH A NEW POWER OF ATTORNEY
`sussrnureu OXAZOLIDINONES AND
`
`AND
`THEIR use lN THE FIELD or BLOOD...
`CHANGE OF CORRESPONDENCE ADDRESS
`119g7_QQo30_U3
`
`I hereby revoke all previous powers of attorney given in the above-identified patent.
`D A Power of Attorney is submitted herewith.
`OR
`
`
`
`
`
`“"9
`
`
`
`
`
`
`
`
`
`
`
`
`
`I hereby appoint Practitioner(s) associated with the following Customer Number as mylour
`altorneyts) or agent(s) with respect to the patent identified above, and to transact all business In
`the United States Patent and Trademark Office connected therewith:
`OR
`
`28416
`
`I hereby appoint Practltioner(s) named below as my/our attorneyts) or agent(s) with respect to the patent Identified
`above, and to transact all business in the United States Patent and Trademark Office connected therewith:
`.
`Registration
`.
`Registration
`Practitronerts) Name
`Practrtloner(s) Name
`
`
`
`
`
`Please recognize or change the correspondence address for the above~identllied patent to:
`“-1 The address associated with the above-mentioned Customer Number.
`OR
`
`
`
`
`
`
`
`
`
`
`
`23416
`
`
`
`'3? The address associated with Customer Number:
`OR
`
`Flrrn or
`
`Individual Name
`
`
`
`
`am the:
`
`
`
` ——l
`
`D inventor, having ownership ofthe patent.
`OR
`
`
`
`
`Patent owner.
`Statement under 37 CPR 3. 73(b) (Form PTO/SB/96) submitted herewith or filed on
`
`
`
`_A. _V ,
`
`
`
`I
`‘V
`_
`|..
`Name
`I
`Tltleandcompany 3'
`
`than ans signature ts required, see baiow”.
`
` NOTE: Signatures of all the inventors or patonto
`ars of the entire interest urthalrrepreserIl.ative(s) are required. Submit multiple forms if more
`forms are submitted.
`
`
`D ‘Total of
`1
`
`
`
`4393856
`
`1
`
`0011
`
`0011
`
`

`
`Electronic Acknowledgement Receipt
`
`10625457
`
`Application Number:
`
`12027553
`
`International Application Number:
`
`Confirmation Number:
`
`Title of Invention:
`
`SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD
`COAGULAHON
`
`First Named Inventor/Applicant Name:
`
`Alexander Straub
`
`Customer Number:
`
`23416
`
`Christine Hansen/Amy Hamm
`
`Filer Authorized By:
`
`Christine Hansen
`
`Attorney Docket Number:
`
`11987-00030-US
`
`Receipt Date:
`
`29-JU L—201 1
`
`Filing Date:
`
`07-FEB—2008
`
`Time Stamp:
`
`10:16:18
`
`Application Type:
`
`Utility under 35 USC111(a)
`
`Payment information:
`
`Submitted with Payment
`
`File Listing:
`
`Document
`Number
`
`Document Description
`
`(if appl.)
`
`File Size(Bytes)/
`Message Digest
`141585
`
`Multi
`
`Part /.zip
`
`Pages
`
`860_POA.pdf
`
`4ca6bc041446c4f29fdcf40dc28c8baccdd6 1
`77f
`
`0012
`
`0012
`
`

`
`Multipart Description/PDF files in .zip description
`
`Assigneeshowing ofownershipper37CFR3.73(b).
`
`Information:
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO ofthe indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`lfa new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`lfa timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/E0/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`lfa new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and ofthe International Filing Date (Form PCT/R0/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0013
`
`0013
`
`

`
`PTO/SB/96 (07-09)
`Approved for use through 07/31/2012. OMB 0651-0031
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paerwork Reduction Act of 1995, no ersons are reuired to res ond to a collection of information unless it clisla s a valid OMB control number.
`
`STATEMENTUNDER37CFR3JMbl
`
`Applicant/Patent Owner:
`
`Alexander Straub et al.
`
`September 8, 2009
`Filed/Issue Date:
`7,585,860
`Application No./Patent No.:
`Titled:
`SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD
`COAGULATlON
`
`Bayer Pharma Aktiengesellschaft
`(Name of Assignee)
`states that it is:
`
`, a
`
`Corporation
`(Type of Assignee, e.g., corporation, partnership, university, govemment agency, etc.)
`
`1.
`
`the assignee of the entire right, title, and interest in;
`
`2. D an assignee of less than the entire right, title, and interest in
`(The extent (by percentage) of its ownership interest is
`
`%); or
`
`3. El an assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)
`the patent application/patent identified above by virtue of either:
`
`A. D An assignment from the inventor(s) of the patent application/patent identified above. The assignment was
`recorded in the United States Patent and Trademark Office at Reel
`,
`Frame
`, or for which a copy thereof is attached.
`
`OR
`
`B_
`
`A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:
`1. From:
`Alexander Straub et at.
`T0:
`BayerAktiengesellschaft
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`020729
`
`, Frame
`
`0104
`
`, or for which a copy thereof is attached.
`
`Bayer Healthcare Aktiengesellschaft
`To:
`Bayer Aktiengesellschaft
`2. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`020729
`
`, Frame
`
`0125
`
`, or for which a copy thereof is attached.
`
`Bayer Schering Pharma AG
`To:
`Bayer Healthcare AG
`3. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`Reel
`
`022520
`
`, Frame
`
`0150
`
`, or for which a copy thereof is attached.
`
`Additional documents in the chain of title are listed on a supplemental sheet(s).
`
`As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the
`assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.
`
`[NOTE: A separate copy (i_e., a true copy of the original assignment document(s)) must be submitted to Assignment
`Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. E MPEP 302.08]
`
`The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.
`
`/Christine M. Hansen/
`Signature
`
`Christine M. Hansen
`Printed or Typed Name
`
`July 29, 2011
`Date
`
`V
`
`Attorney for Assignee
`Title
`
`4410883
`
`0014
`
`0014
`
`

`
`SUPPLEMENTAL SHEET FOR USE WITH PTO/SB/96 (07-09)
`
`Bayer Schering Pharma AG
`To:
`Bayer Healthcare AG
`4. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`, or for which a copy thereof is attached.
`, Frame
`022575
`Reel
`To:
`Bayer Pharma Aktiengesellschaft
`Bayer Schering Pharma AG
`5. From:
`The document was recorded in the United States Patent and Trademark Office at
`
`0337
`
`Reel
`
`026661
`
`, Frame
`
`0406
`
`, or for which a copy thereof is attached.
`
`0015
`
`0015
`
`

`
`
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`www.uspto.gov
`
`APPLICATION NO.
`
`12/027,553
`
`ISSUE DATE
`
`09/08/2009
`
`PATENT NO.
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`7585860
`
`11987—00030—US
`
`5078
`
`23416
`
`7590
`
`08/19/2009
`
`CONNOLLY BOVE LODGE & HUTZ, LLP
`P 0 BOX 2207
`WILMINGTON, DE 19899
`
`The projected patent number and issue date are specified above.
`
`ISSUE NOTIFICATION
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(application filed on or after May 29, 2000)
`
`The Patent Term Adjustment is 0 day(s). Any patent to issue from the above—identified application will include
`an indication of the adjustment on the front page.
`
`If a Continued Prosecution Application (CPA) was filed in the above—identified application, the filing date that
`determines Patent Term Adjustment is the filing date of the most recent CPA.
`
`Applicant will be able to obtain more detailed information by accessing the Patent Application Information
`Retrieval (PAIR) WEB site (http://pair.uspto. gov).
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the
`Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee
`payments should be directed to the Customer Service Center of the Office of Patent Publication at
`(571)-272-4200.
`
`APPLICANT(S) (Please see PAIR WEB site http://pair.uspto. gov for additional applicants):
`
`Alexander Straub, Wuppertal, GERMANY;
`Thomas Lampe, Wuppertal, GERMANY;
`Jens Pohlmann, Wuppertal, GERMANY;
`Susanne Rohrig, Essen, GERMANY;
`Elisabeth Perzbom, Wuppertal, GERMANY;
`Karl-Heinz Schlemmer, Wuppertal, GERMANY;
`Joseph Pernerstorfer, Wuppertal, GERMANY;
`
`IR103 (Rev. 11/05)
`
`0016
`
`0016
`
`

`
`PART B -FEE(S) TRANSMITTAL
`
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-4450
`or Lg (571) 273-2885
`through 5 should be compieted where
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees wili be mailed to the current correspondence address
`as indicated uniess corrected below or directed otherwise in Block 3, by (a) specifying a new correspondence address; andlor (b) indicating a separate "FEE ADDRESS"
`for maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (NOWU5=B1°°5<1f°”nY€h3“s=°f°“=‘r===)
`
`Note: A certificate of mailing can only be used for domestic maiiings of the
`Fee(s) Transmittal. This certificate cannot be used for any other accompanying
`papers. Each additional paper, such as an assignment or formal drawing, must
`have its own certificate of mailing or transmission.
`Certificate of Mailing or Transmission
`I herebycertify that this Fee(s) Transmittal 13 being deposited with the United
`States Postal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted to the USPTO (STE) 273-2885, on the date indicated below.
`Sara A. Maloney
`(Deposilnfs name
`
`
`/Sara A. Maloneyl
`(Signature)
`
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO
`
`FIRST NAMED INVENTOR
`
`CONNOLLY BOVE LODGE & HU1-Z LL13
`1007 North Orange Street
`P_ 0_ Box 2207
`Wilmington, Delaware 19899-2207
`
`
`
`APPLICATION NO.
`
`FILING DATE
`
`12/027,553
`
`02/07/2008
`
`Alexander Straub
`
`11987-0003 0—US
`
`5078
`
`TITLE OF INVENTION:
`
`SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION
`
`APPLN. TYPE
`Non-Provisional
`EXAMINER
`Rebecca L. Anderson
`
`SMALL ENTITY
`no
`
`ISSUE FEE
`$1,510.00
`ART UNIT
`1626
`
`PUBLICATION FEE
`$300.00
`CLASS-SUBCLASS
`5 I 4-236800
`
`TOTAL FEE(S) DUE
`$1,810.00
`
`DATE DUE
`08/24/2009
`
`1. Change of correspondence address or indication of "Fee
`Address” (37 CFR 1.363).
`|:| Change of correspondence address (or Change of
`Correspondence Address form PTO/SB/122) attached.
`|:| "Fee Address" indication (or "Fee Address" Indication
`form PTOISB/4'7; Rev 03-02 or more recent) attached.
`Use of a Customer Number is re aired.
`
`
`
`2. For printing on the patent front page, list
`Connolly Bove Lodge & Hutz LLP
`1
`(1)
`the names of up to 3
`registered patent
`attorneys or agents OR, alternatively, '
`(2) the name of a single finn (having as a member
`2
`a registered attorney or agent) and the names of
`up to 2 registered patent attorneys or agents. If no
`name is listed, no name will be printed.
`
`3
`
`3. ASSTGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`PLEASE NOTE: Unless an assignee is identified beiow, no assignee data will appear on the patent. If an assignee is identified below, the document has been fried
`for rceordation as set forth in 37 CFR 3.1 1. Completion ofthis form is NOT a substitute for filing an assignment.
`-
`(A) NAIVIE OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`Bayer Schering Phanna Aictiengesellschafi
`
`Bertin, Germany
`
`Please check the appropriate assignee category or categories (will not be printed on the patent) : E! Individual
`42:. The following fee(s) are enclosed:
`4b. Payment of Fee(s):
`Issue Fee
`'3 A check in the amount ofthe fee(s) is enclosed.
`
`Corporation or other private group entity El Government
`
`Publication Fee (No small entity discount permitted)
`
`Payment by credit card.
`
`El Advance Order-# of Copies
`
`B The Director is hereby auihorized by charge the required fee(s), or credit any overpayment, to
`Deposit Account Number
`03.2775
`
`5. Change in Entity Status (from status indicated above)
`[3 a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27. B b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR l.27(g)(2).
`The Director of the USPTO is requested to apply the Issue Fee and Publication Fee (if any) or to reapply any previously paid issue fee to the application identified